Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Marinomed, Zumtobel (11/10/2024)

13.10.2024

Marinomed: Marinomed Biotech AG announced that, after a thorough review of existing offers, the Management Board today decided to enter contract negotiations for the sale of the Carragelose portfolio in the form of an asset deal. The Company selected the potential buyer based on a combination of favorable purchase price, transaction security and strategic fit, thereby providing a long-term perspective for the Company. The actual implementation of the transaction depends on the outcome of the specific negotiations, the conclusion of the respective transaction documents, the approval of the Supervisory Board and the General Shareholder Assembly, as well as the continuation of the Company after the restructuring process. In addition, due to the ongoing restructuring process, approvals from the insolvency administrator and the insolvency court are necessary. These approvals have not yet been obtained.

Zumtobel: The Supervisory Board of the Zumtobel Group has extended the contract of Chief Executive Officer Alfred Felder (61), which is due to expire as of 31 July 2025, until 30 September 2027. With the repeated renewal of his contract, the Supervisory Board focuses on continuity in the Management Board of the Zumtobel Group and recognises the achievements of Alfred Felder, who has navigated the company through difficult times. On 1 February 2018, Alfred Felder took over the role of Acting President of the Management Board; on 8 June 2018, he was appointed Chief Executive Officer (CEO).
Zumtobel: weekly performance: 0.36%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (11/10/2024)


Partners









latest 21st Austria

21st Austria weekly - Marinomed, Zumtobel (11/10/2024)


13.10.2024, 1628 Zeichen



Marinomed: Marinomed Biotech AG announced that, after a thorough review of existing offers, the Management Board today decided to enter contract negotiations for the sale of the Carragelose portfolio in the form of an asset deal. The Company selected the potential buyer based on a combination of favorable purchase price, transaction security and strategic fit, thereby providing a long-term perspective for the Company. The actual implementation of the transaction depends on the outcome of the specific negotiations, the conclusion of the respective transaction documents, the approval of the Supervisory Board and the General Shareholder Assembly, as well as the continuation of the Company after the restructuring process. In addition, due to the ongoing restructuring process, approvals from the insolvency administrator and the insolvency court are necessary. These approvals have not yet been obtained.

Zumtobel: The Supervisory Board of the Zumtobel Group has extended the contract of Chief Executive Officer Alfred Felder (61), which is due to expire as of 31 July 2025, until 30 September 2027. With the repeated renewal of his contract, the Supervisory Board focuses on continuity in the Management Board of the Zumtobel Group and recognises the achievements of Alfred Felder, who has navigated the company through difficult times. On 1 February 2018, Alfred Felder took over the role of Acting President of the Management Board; on 8 June 2018, he was appointed Chief Executive Officer (CEO).
Zumtobel: weekly performance: 0.36%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (11/10/2024)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

kapitalmarkt-stimme.at daily voice 13/365: Die KESt-Behaltefrist, warum sie das heisseste Thema ist und eine kurze Frist her muss




 

Bildnachweis

Aktien auf dem Radar:Kapsch TrafficCom, Austriacard Holdings AG, EuroTeleSites AG, Flughafen Wien, Warimpex, Mayr-Melnhof, Erste Group, ATX, ATX Prime, ATX TR, OMV, Wienerberger, Cleen Energy, DO&CO, Pierer Mobility, Stadlauer Malzfabrik AG, Semperit, Strabag, Josef Manner & Comp. AG, Agrana, Amag, Rosenbauer, Oberbank AG Stamm, RHI Magnesita, EVN, Palfinger, Österreichische Post, Telekom Austria, Uniqa, VIG.


Random Partner

Evotec
Evotec ist ein Wirkstoffforschungs- und -entwicklungsunternehmen, das in Forschungsallianzen und Entwicklungspartnerschaften mit Pharma- und Biotechnologieunternehmen, akademischen Einrichtungen, Patientenorganisationen und Risikokapitalgesellschaften Ansätze zur Entwicklung neuer pharmazeutischer Produkte vorantreibt.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten